Ceftolozane-Tazobatam for febrile neutropenia treatment in hematologic malignancy patients colonized by multi-resistant Enterobacteriaceae: preliminary results from a prospective cohort study Ceftolozane-Tazobatam for febrile neutropenia

Main Article Content

Francesco Marchesi
Fabrizio Ensoli
Irene Terrenato
Elena Papa
Fulvia Pimpinelli
Grazia Prignano
Antonio Spadea
Ilaria Cavallo
Enea Gino Di Domenico
Luigi Toma
Andrea Mengarelli
(*) Corresponding Author:

Abstract

NA


Downloads month by month

Downloads

Download data is not yet available.

Article Details

References

1. Cattaneo C, Di Blasi R, Skert C, Candoni A, Martino B, Di Renzo N, et al; SEIFEM Group. Bloodstream infections in haematological cancer patients colonized by multidrug-resistant bacteria. Ann Hematol. 2018;97:1717-1726. doi: 10.1007/s00277-018-3341-6.
2. Girmenia C, Bertaina A, Piciocchi A, Perruccio K, Algarotti A, Busca A, et al; Gruppo Italiano Trapianto di Midollo Osseo (GITMO) and Associazione Microbiologi Clinici Italiani (AMCLI). Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey. Clin Infect Dis. 2017;65:1884-1896. doi: 10.1093/cid/cix690.
3. Verlinden A, Mikulska M, Knelange NS, Averbuch D, Styczynski J; Infectious Diseases Working Party (IDWP) of the European Group for Blood and Marrow Transplantation Group (EBMT) Current antimicrobial practice in febrile neutropenia across Europe and Asia: the EBMT Infectious Disease Working Party survey. Bone Marrow Transplant. 2020 Feb 11. doi: 10.1038/s41409-020-0811-y [Epub ahead of print].
4. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving sepsis campaign:International guidelines for management of sepsis and septic shock, 2016. Intensive Care Med. 2017;43:304-377. doi: 10.1007/s00134-017-4683-6.
5. Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18:3038-3051. doi: 10.1200/JCO.2000.18.16.3038.
6. Marchesi F, Cattaneo C, Criscuolo M, Delia M, Dargenio M, Del Principe MI, et al.; Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) Group. A bronchoalveolar lavage-driven antimicrobial treatment improves survival in hematologic malignancy patients with detected lung infiltrates: a prospective multicenter study of the SEIFEM group. Am J Hematol. 2019;94:1104-1112. doi: 10.1002/ajh.25585.
7. Di Domenico EG, Rimoldi SG, Cavallo I, D'Agosto G, Trento E, Cagnoni G, et al. Microbial biofilm correlates with an increased antibiotic tolerance and poor therapeutic outcome in infective endocarditis. BMC Microbiol. 2019;19:228. doi: 10.1186/s12866-019-1596-2.
8. Karaiskos I, Giamarellou H. Carbapenem-sparing strategies for ESBL producers: when and how? Antibiotics. (Basel) 2020;9. doi: 10.3390/antibiotics9020061.
9. Corcione S, Lupia T, Maraolo AE, Mornese Pinna S, Gentile I, et al. Carbapenem-sparing strategy: carbapenemase, treatment, and stewarship. Curr Opin Infect Dis. 2019;32:663-673. doi: 10.1097/QCO.0000000000000598.
10. Fernández-Cruz A, Alba N, Semiglia-Chong MA, Padilla B, Rodríguez-Macías G, Kwon M, et al. A case-control study of real-life experience of ceftolozane-tazabactam in patients with hematologic malignancy and Pseudomonas aeruginosa infection. Antimicrob Agents Chemother. 2019;63(2):e02340-18. doi: 10.1128/AAC.02340-18.

Most read articles by the same author(s)